Ruti Aga banned six years: forged prescription and an old prescription pad end 32-year-old marathon star's career

Ethiopian marathon runner Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). This ruling is not the result of an ordinary doping violation. It is the story of a far graver moral collapse, in which a family member issued a forged medical prescription in her name to justify the use of a prohibited substance. The clinic on whose letterhead the prescription was written did not exist. The person who wrote it as a "doctor" was not registered in the medical profession. And when the AIU investigated, that clinic stated clearly that no such prescription had ever been issued. After three separate verification failures, Aga had no escape route left.

This whole story is a lesson in how an athlete can gamble an entire career in the haste to hide an injury. It also shows that, in the eyes of the AIU, lying or fabricating documents often weighs heavier than the substance itself for which the athlete was caught.

The simple arithmetic of six years

The arithmetic of the sanction is entirely clear. Aga received a two-year ban for the presence of methylprednisolone in her body. Then, when she submitted a forged prescription to mislead the investigation, a further four years was added for that "tampering." Two plus four, six years in total. The ban is deemed to run from 10 September, because she was provisionally suspended from that date. In other words, the time she had already spent out was also counted into this sanction—this is no special relief, merely procedural formality.

That addition is not ordinary. It directly means the AIU panel refused to accept that Aga had "not made any significant mistake" or that she was "innocent." Had she possessed genuine medical records and told the truth instead of manufacturing a prescription, the sanction could have been reduced, or perhaps avoided altogether.

What methylprednisolone is — and the media's big error

A technical point must be made clear here, because it played a decisive role in this case and has been presented incorrectly in most reports. Methylprednisolone is not a "prohibited steroid." It belongs to the class of glucocorticoid medicines, placed in class S9 of the WADA Prohibited List, not in class S1, which covers anabolic steroids. This difference is enormous. Under current rules, glucocorticoids are prohibited only in-competition, and only when administered by injection, orally or rectally. A knee injection given out-of-competition is entirely legal. It becomes a violation only if residues are present in the body at the time of competition.

This means the entire case hinged not on "steroid use" but on the route of administration and the timing relative to the competition. And this is precisely where Aga and her advisers went wrong. A properly managed athlete would either have obtained a Therapeutic Use Exemption (TUE) for this treatment, or followed WADA's prescribed "washout" period. Neither happened. Instead, a forged document was manufactured. That was the one mistake that decided everything else.

The knee injury and the real problem of distance running

Aga stated in the investigation that she took the medicine to treat a knee injury. For distance runners, a glucocorticoid injection in the knee is not unusual—it is a standard practice in sports medicine, especially for knee inflammation or synovitis. But the flip side of this medical logic is that if the treatment had genuinely been legitimate, it could have been proven with real records. Manufacturing a fake prescription means precisely that no real record existed anywhere.

It is also worth noting that chronic knee problems are a familiar professional risk for Ethiopian and Kenyan distance runners. Among marathoners training at heavy volumes, it is one of the most common injuries. And when injury strikes, the pressure to keep up appearances also rises, because in this market athletes' incomes depend substantially on their performances and appearance fees. The cheapest and easiest tool for masking pain is precisely a glucocorticoid injection. The question then arises whether the mistake was the athlete's alone, or also that of a system that did not provide her with medical support.

How weak Aga's medical support was is evidenced by the prescription itself. The person who wrote it was a family member and was not registered in medicine. He claimed he had used "an old prescription pad from his former workplace." But when the AIU investigated, that clinic did not exist. Three separate documentary verifications failed: no clinic, no registration, and no record of the prescription pad.

The 2026 Tokyo legacy and the death of a career

Aga was no ordinary runner. In 2026 she won the Tokyo Marathon, one of the most prestigious marathons in the world. She also finished second three times at World Marathon Majors. Her personal best is understood to be around 2:18:34, recorded at the 2026 Berlin Marathon, where she finished second. These achievements mark her as a genuinely world-class marathoner.

But this ban effectively ends her career in technical terms. A six-year ban at age 32 means she would return at roughly 38. Given the depth and competitiveness of Ethiopian women's marathoning, the probability of selecting a 38-year-old with a doping record for the national team is close to zero. Practically, then, this is a lifetime ban.

One point of relief—or at least of uncertainty—is that the 2026 Tokyo victory and earlier results are not automatically annulled. The violation is linked to the March race, which took place in a later year. Unless evidence of an earlier violation is found, older records stand. The AIU, however, did not state the scope of disqualification. But under normal practice, the result and prize money of that March race should be considered void.

China's race circuit and the ethical crisis

Aga won a half marathon in China in March, and her doping test came back positive after that very race. The race was presumably a World Athletics Label-tier event, with an elite women's field and in-competition testing. Such races are an attractive source of income for East African marathoners—they offer good earnings between Major marathons and carry lower risk. But this same tier has now become the most heavily tested territory for the AIU. The appearance-fee economy and the testing economy are colliding in the same races.

This case is part of a larger pattern. In AIU's East African road-racing cases over recent years, one thing has repeatedly surfaced—first a substance violation, and then a document or statement fabricated to conceal or explain it away. This suggests the enforcement frontier has shifted from "detection" to "document verification." Aga's case is not isolated.

The appeal option and the bigger question

Aga has the option of appealing to the Court of Arbitration for Sport (CAS), usually within about 21 days of the decision. But in document-based cases the chances of overturning are slim, because the question here was not only about the drug but about forgery.

An uncomfortable question in this case is also that the substance for which she was sanctioned has no proven benefit for endurance performance. A six-year ban for a glucocorticoid is evidence both of the AIU's seriousness and, for many observers, of disproportionately harsh action against African road-running athletes.

Conclusion

Ruti Aga's story is a reminder that in doping cases the real mistake is sometimes not the substance but the method of concealment. She had a legitimate defence—therapeutic medicine, a genuine knee injury and correct timing management. But the forged prescription destroyed that defence herself.

This is not merely one athlete's mistake. It is also the mistake of a weak medical system in which, in place of a proper doctor, a proper adviser and proper records, a family member and an old prescription pad were deemed sufficient. And until the economics of road racing and the structure of medical support in training camps at this level change, such cases will keep coming.